Adial Pharmaceuticals, Inc - Common Stock (NQ:ADIL)

3.010 +0.060 (+2.03%)

Streaming Delayed Price Updated: 3:37 PM EDT, Jul 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adial Pharmaceuticals, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

May 01, 2025

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 01, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 01, 2025

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders ↗

May 01, 2025

Adial secures USPTO patent for AD04, expanding coverage to treat alcohol and opioid-related disorders in patients with genetic markers.

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 21, 2025

Via Benzinga

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder ↗

February 25, 2025

Adial Pharmaceuticals secured FDA support for its AD04 bridging strategy, paving the way for Phase 3 trials in 2025 after confirming bioequivalence.

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders ↗

February 12, 2025

Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics study supporting its Phase 3 trial.

Via Benzinga

Topics Intellectual Property

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder ↗

January 29, 2025

Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality, and no food effect.

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations ↗

December 03, 2024

Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy.

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 14, 2024

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder ↗

November 14, 2024

Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.

Via Benzinga

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 14, 2024

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate ↗

October 17, 2024

Adial Pharmaceuticals secures a new patent allowance for AD04, enhancing its precision medicine approach for treating alcohol use disorder. Topline results from AD04's latest study are expected in Q4...

Via Benzinga

Topics Intellectual Property

ADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024 ↗

August 13, 2024

Adial Pharmaceuticals just reported results for the second quarter of 2024.

Via InvestorPlace

EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder ↗

August 13, 2024

Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal...

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4 ↗

August 07, 2024

Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results...

Via Benzinga

Gold Moves Higher; Coca-Cola Increases FY24 Forecast ↗

July 23, 2024

Via Benzinga

Why Is Serve Robotics (SERV) Stock Down Today? ↗

July 23, 2024

Serve Robotics stock is down on Tuesday after the company revealed the pricing of warrants for SERV shares in a private placement.

Via InvestorPlace

Why Is Jaguar Health (JAGX) Stock Down 55% Today? ↗

July 23, 2024

Jaguar Health stock is down on Tuesday as JAGX investors react to failed results from a Phase 3 clinical trial of crofelemer.

Via InvestorPlace

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 23, 2024

Via Benzinga

Crude Oil Down 2%; GE Aerospace Earnings Top Views ↗

July 23, 2024

Via Benzinga

Why Is Adial Pharmaceuticals (ADIL) Up 61% Today? ↗

July 23, 2024

Adial Pharmaceuticals stock is up with heavy trading of ADIL after providing investors with an update on its AD04 clinical trial.

Via InvestorPlace

US Stocks Edge Higher; General Motors Posts Upbeat Earnings ↗

July 23, 2024

Via Benzinga

EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder ↗

July 23, 2024

Adial Pharmaceuticals progresses to the second cohort in the AD04 pharmacokinetics study for Alcohol Use Disorder. This study, involving up to 30 healthy volunteers, will provide critical insights for...

Via Benzinga

ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023 ↗

June 27, 2024

ADIL stock results show that Adial Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder ↗

June 20, 2024

Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching...

Via Benzinga

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

June 06, 2024

Via ACCESSWIRE

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 ↗

June 05, 2024

These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.

Via InvestorPlace

EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder ↗

June 05, 2024

Adial Pharmaceuticals starts dosing in pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. Topline results in early Q4 2024.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 24, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.